Research programme: cancer therapeutics - Array BioPharma/Loxo Oncology

Drug Profile

Research programme: cancer therapeutics - Array BioPharma/Loxo Oncology

Alternative Names: LOXO-102; LOXO-103; LOXO-104; LOXO-195; LOXO-292

Latest Information Update: 07 Apr 2016

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Loxo Oncology
  • Class Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Mar 2016 Loxo Oncology has patent protection for LOXO 195 and anti-TRK molecules worldwide (Loxo Oncology 10-K, March 2015)
  • 10 Nov 2015 Loxo Oncology intends to initiate a phase I trial for RET inhibitor in late 2016 or early 2017
  • 05 Aug 2015 Loxo Oncology suspends IND filing for Cancer, until target validation is complete
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top